TCGA-E9-A1NG-01A-21R-A14M-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 26
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.680
- ANGIOGENESIS+0.640
- TGF_BETA_SIGNALING+0.520
- UV_RESPONSE_DN+0.470
- HEDGEHOG_SIGNALING+0.460
- INFLAMMATORY_RESPONSE+0.450
- KRAS_SIGNALING_UP+0.450
- TNFA_SIGNALING_VIA_NFKB+0.450
- COAGULATION+0.430
- COMPLEMENT+0.430
Top 10 suppressed
- MYC_TARGETS_V2-0.570
- E2F_TARGETS-0.530
- G2M_CHECKPOINT-0.460
- MYC_TARGETS_V1-0.380
- OXIDATIVE_PHOSPHORYLATION-0.340
- DNA_REPAIR-0.300
- BILE_ACID_METABOLISM-0.240
- PEROXISOME-0.230
- ADIPOGENESIS-0.170
- SPERMATOGENESIS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM6454738 | — | A | 0.941 |
| 2 | TCGA-AN-A0XN-01A-21R-A109-07 | — | A | 0.934 |
| 3 | TCGA-AO-A03U-01B-21R-A10J-07 | — | D | 0.922 |
| 4 | TCGA-46-3767-01A-01R-0980-07 | — | cohortSQ1 | 0.921 |
| 5 | SRR8518425 | — | A | 0.920 |
| 6 | TCGA-77-8008-01A-21R-2187-07 | — | cohortSQ1 | 0.917 |
| 7 | TCGA-BH-A208-01A-11R-A157-07 | — | A | 0.916 |
| 8 | SRR25617929 | — | A | 0.914 |
| 9 | TCGA-BH-A0DI-01A-21R-A12P-07 | — | A | 0.912 |
| 10 | TCGA-AN-A0FN-01A-11R-A034-07 | — | A | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.680 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.640 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.520 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.470 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.450 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.450 | Inavolisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| HYPOXIA | 0.430 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.380 | Inavolisib | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.320 | Idelalisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |